Literature DB >> 15375658

Epithelial hyaluronic acid and CD44v6 are mutually involved in invasion of colorectal adenocarcinomas and linked to patient prognosis.

Martin Köbel1, Wilko Weichert, Katharina Crüwell, Wolfgang D Schmitt, Christine Lautenschläger, Steffen Hauptmann.   

Abstract

Desmoplastic stroma of colorectal adenocarcinomas contains a variety of extracellular matrix molecules, including hyaluronic acid (HA). Overexpression of the HA receptor CD44 and, in particular, its splicing variant CD44v6 has been described as a prognostic factor for patients with colorectal adenocarcinomas in some studies, but converse reports also exist. Our hypothesis is that these divergent results may be related to the fact that the function of CD44v6 depends on the HA content of cell-surrounding matrix. Therefore, we studied the expression of HA and CD44v6 in tissue samples of 145 patients suffering from colorectal adenocarcinomas using immunohistochemistry. Expression of HA was separately evaluated in tumor epithelium and stroma. We additionally examined the influence of HA on invasion and adhesion of colorectal adenocarcinoma cells in vitro. The results show that epithelial HA expression was not correlated with tumor stage but with lymph-node or distant metastasis. Patients with tumors expressing epithelial HA had a decreased overall survival ( P=0.017) as well as tumors with coexpression of epithelial HA and CD44v6 ( P=0.011). The latter issue remained an independent prognostic factor in multivariate analysis (relative risk 5.06; 95% confidence interval, 1.18-21.57; P=0.028). HA exclusively stimulated in vitro invasion of CD44v6-expressing cells. This stimulation was partly reversed by an anti-CD44v6 antibody. Our findings suggest that the adverse prognostic effect of CD44v6 in colorectal adenocarcinoma might be restricted to those tumors that have pericellular HA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15375658     DOI: 10.1007/s00428-004-1095-0

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  23 in total

1.  CD44 variant exons in leukemia and lymphoma.

Authors:  Elif Akisik; Sevil Bavbek; Nejat Dalay
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

2.  CD44 is required for two consecutive steps in HGF/c-Met signaling.

Authors:  Véronique Orian-Rousseau; Linfeng Chen; Jonathan P Sleeman; Peter Herrlich; Helmut Ponta
Journal:  Genes Dev       Date:  2002-12-01       Impact factor: 11.361

3.  Decreased expression of CD44 splicing variants in advanced colorectal carcinomas.

Authors:  S Weg-Remers; M Anders; B von Lampe; E O Riecken; G Schüder; G Feifel; M Zeitz; A Stallmach
Journal:  Eur J Cancer       Date:  1998-09       Impact factor: 9.162

4.  The positive relationship between the expression of CD44 variant 6 and prognosis in colorectal cancer.

Authors:  Z Nihei; W Ichikawa; K Kojima; S Togo; T Miyanaga; R Hirayama; Y Mishima
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

5.  Immunohistochemical expression of the CD44 variant 6 in colorectal adenocarcinoma.

Authors:  T Ishida
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

6.  A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin's lymphoma.

Authors:  Y Yakushijin; J Steckel; S Kharbanda; R Hasserjian; D Neuberg; W Jiang; I Anderson; M A Shipp
Journal:  Blood       Date:  1998-06-01       Impact factor: 22.113

7.  Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis.

Authors:  K M Ropponen; M J Eskelinen; P K Lipponen; E Alhava; V M Kosma
Journal:  Scand J Gastroenterol       Date:  1998-03       Impact factor: 2.423

8.  Tumor cell-associated hyaluronan as an unfavorable prognostic factor in colorectal cancer.

Authors:  K Ropponen; M Tammi; J Parkkinen; M Eskelinen; R Tammi; P Lipponen; U Agren; E Alhava; V M Kosma
Journal:  Cancer Res       Date:  1998-01-15       Impact factor: 12.701

9.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.

Authors:  U Günthert; M Hofmann; W Rudy; S Reber; M Zöller; I Haussmann; S Matzku; A Wenzel; H Ponta; P Herrlich
Journal:  Cell       Date:  1991-04-05       Impact factor: 41.582

10.  Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma.

Authors:  Carsten Denkert; Martin Köbel; Sören Pest; Ines Koch; Stefan Berger; Michael Schwabe; Antje Siegert; Angela Reles; Bernd Klosterhalfen; Steffen Hauptmann
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

View more
  14 in total

1.  S100A4 expression in xenograft tumors of human carcinoma cell lines is induced by the tumor microenvironment.

Authors:  Hilde Ljones Wetting; Elin Hadler-Olsen; Synnøve Magnussen; Oddveig Rikardsen; Sonja E Steigen; Elisabeth Sundkvist; Thrina Loennechen; Premasany Kanapathippillai; Hanne Kildalsen; Jan-Olof Winberg; Lars Uhlin-Hansen; Gunbjørg Svineng
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Role of cancer stem cell marker CD44 in gastric cancer: a meta-analysis.

Authors:  Wei Wang; Li-Ping Dong; Ning Zhang; Cheng-Hai Zhao
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 3.  Hyaluronic acid in digestive cancers.

Authors:  Ruo-Lin Wu; Lei Huang; Hong-Chuan Zhao; Xiao-Ping Geng
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-17       Impact factor: 4.553

4.  Stromal impact on tumor growth and lymphangiogenesis in human carcinoma xenografts.

Authors:  Elin Hadler-Olsen; Hilde Ljones Wetting; Oddveig Rikardsen; Sonja E Steigen; Premasany Kanapathippillai; Reidar Grénman; Jan-Olof Winberg; Gunbjørg Svineng; Lars Uhlin-Hansen
Journal:  Virchows Arch       Date:  2010-10-03       Impact factor: 4.064

5.  Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival.

Authors:  David F Schaeffer; Daniel R Owen; Howard J Lim; Andrew K Buczkowski; Stephen W Chung; Charles H Scudamore; David G Huntsman; Sylvia S W Ng; David A Owen
Journal:  BMC Cancer       Date:  2010-02-23       Impact factor: 4.430

6.  Overexpression of DEK is an indicator of poor prognosis in patients with gastric adenocarcinoma.

Authors:  Yingfu Ou; Rongjun Xia; Fanyong Kong; Xiaokang Zhang; Shengjin Yu; Lili Jiang; Linlin Zheng; Lijuan Lin
Journal:  Oncol Lett       Date:  2016-01-26       Impact factor: 2.967

7.  CD44v6 down-regulation is an independent prognostic factor for poor outcome of colorectal carcinoma.

Authors:  Lili Wang; Qin Liu; Dongliang Lin; Maode Lai
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

8.  Stromal hyaluronan accumulation is associated with low immune response and poor prognosis in pancreatic cancer.

Authors:  Kyösti Tahkola; Maarit Ahtiainen; Jukka-Pekka Mecklin; Ilmo Kellokumpu; Johanna Laukkarinen; Markku Tammi; Raija Tammi; Juha P Väyrynen; Jan Böhm
Journal:  Sci Rep       Date:  2021-06-09       Impact factor: 4.379

9.  Plectin as a prognostic marker in non-metastatic oral squamous cell carcinoma.

Authors:  Oddveig G Rikardsen; Synnøve N Magnussen; Gunbjørg Svineng; Elin Hadler-Olsen; Lars Uhlin-Hansen; Sonja E Steigen
Journal:  BMC Oral Health       Date:  2015-08-26       Impact factor: 2.757

10.  Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC).

Authors:  Synnøve Magnussen; Oddveig G Rikardsen; Elin Hadler-Olsen; Lars Uhlin-Hansen; Sonja E Steigen; Gunbjørg Svineng
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.